HK Stock Market Move | EB ENVIRONMENT(00257) up more than 4% in midday trading, the company continues to advance the A+H listing, which is beneficial for future overseas expansion strategy.
Guangda Environment (00257) rose more than 4% during trading hours. As of the time of writing, it had risen by 3.53% to 4.99 Hong Kong dollars, with a trading volume of 1.15 billion Hong Kong dollars.
EB ENVIRONMENT rose more than 4% during trading, and at the time of writing, it had risen by 3.53%, reaching 4.99 Hong Kong dollars, with a turnover of 1.15 billion Hong Kong dollars.
In terms of news, in November of last year, EB ENVIRONMENT announced its plans to issue no more than 800 million RMB shares on the Shenzhen Stock Exchange. On December 26th, the website of the China Securities Regulatory Commission showed that EB ENVIRONMENT had completed the guidance filing registration with the Shenzhen Securities Regulatory Bureau, initiating the listing guidance.
Guangyin International released a research report stating that if EB ENVIRONMENT could successfully list both in A shares and H shares, it would not only help enhance the company's long-term value, but also open up financing channels in the A-share market. Tianfeng believes that this issuance can provide more sufficient funding reserves for the company's future overseas expansion. They continue to have a positive outlook on China's waste incineration industry going overseas.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276) receives the clinical trial approval notification for HRS-7535 tablets.

Jiangsu Hengrui Pharmaceuticals' New Drug Injection for Carirelizumab Monoclonal Antibody Combined with Apatinib Mesylate Tablets for a New Indication has been Accepted for Market Approval Application.

Yum China (09987) spent 7.7225 million Hong Kong dollars on January 28 to repurchase 19,500 shares.
Jiangsu Hengrui Pharmaceuticals (01276) receives the clinical trial approval notification for HRS-7535 tablets.

Jiangsu Hengrui Pharmaceuticals' New Drug Injection for Carirelizumab Monoclonal Antibody Combined with Apatinib Mesylate Tablets for a New Indication has been Accepted for Market Approval Application.

Yum China (09987) spent 7.7225 million Hong Kong dollars on January 28 to repurchase 19,500 shares.

RECOMMEND

Late‑Night Broad Rally As Chip Sector Receives Major Boost: Price Hikes Announced
29/01/2026

Embodied Intelligence: From Frenzy To Breakthrough Through Real‑World Deployment
29/01/2026

Dollar Falls To Four‑Year Low, Trump “Adds Fuel To The Fire”: Not Worried, Dollar Performing Well, Will Find A Reasonable Level
29/01/2026


